CORRIGENDUM to: Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications (Nature Reviews Drug Dicovery, 10.1038/nrd.2017.194 (2017);Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications

Nature Reviews Drug Discovery

Volumn 17, Issue 1, 2018, Pages 19-33

  Shih, Hsin Pei ^a   Zhang, Xiaodan ^a   Aronov, Alex M ^a  

^a VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 PHOSPHONOMETHYLPIPECOLIC ACID; ALEGLITAZAR; ALVAMELINE; CEFDITOREN; CEFEPIME; CETIRIZINE; CIPROFLOXACIN; CORIFOLLITROPIN ALFA; DARUSENTAN; DICLOFENAC; EMAKALIM; ERTAPENEM; FIBRINOGEN; GOSERELIN; HOMOTAURINE; LENVATINIB; LEVOFLOXACIN; LEXIPAFANT; LONAPALENE; MOXIFLOXACIN; NICARDIPINE; NOLPITANTIUM; OLANZAPINE; OMEPRAZOLE; PACTIMIBE; PAMAPIMOD; PONEZUMAB; SEMAGACESTAT; TALIBEGRON; NEW DRUG;

AFIBRINOGENEMIA; ALLERGIC CONJUNCTIVITIS; ALZHEIMER DISEASE; ANGINA PECTORIS; ARTICLE; ASTHMA; ATHEROSCLEROSIS; BIPOLAR I DISORDER; BREAST CANCER; CEREBROVASCULAR DISEASE; DRUG INDUSTRY; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DUODENUM ULCER; ESCHERICHIA COLI INFECTION; EYE INFLAMMATION; FEMALE INFERTILITY; HAEMOPHILUS INFECTION; HUMAN; HYPERTENSION; INFORMATION PROCESSING; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; PSORIASIS; RENAL CELL CARCINOMA; RHEUMATOID ARTHRITIS; STREPTOCOCCUS INFECTION; TREATMENT INDICATION; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG DATABASE; DRUG DEVELOPMENT; PRODUCTIVITY; STATISTICS AND NUMERICAL DATA; TRENDS;

CLINICAL TRIALS AS TOPIC; DATABASES, PHARMACEUTICAL; DRUG APPROVAL; DRUG DISCOVERY; DRUG INDUSTRY; DRUGS, INVESTIGATIONAL; EFFICIENCY; HUMANS;

EID: 85039764416     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/NRD.2017.255     Document Type: Erratum

References (84)

1. Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3, 711-715 (2004).
2. Paul, S. M. et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 9, 203-214 (2010).
3. Empfield, J. R. & Leeson, P. D. Lessons learned from candidate drug attrition. IDrugs 13, 869-873 (2010).
4. DiMasi, J. A., Feldman, L., Seckler, A. & Wilson, A. Trends in risks associated with new drug development: success rates for investigational drugs. Clin. Pharmacol. Ther. 87, 272-277 (2010).
5. Pammolli, F., Magazzini, L. & Riccaboni, M. The productivity crisis in pharmaceutical R&D. Nat. Rev. Drug Discov. 10, 428-438 (2011).
6. Arrowsmith, J. Trial watch: phase II failures: 2008-2010. Nat. Rev. Drug Discov. 10, 328-329 (2011).
7. Scannell, J. W., Blanckley, A., Boldon, H. & Warrington, B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat. Rev. Drug Discov. 11, 191-200 (2012).
8. Ringel, M., Tollman, P., Hersch, G. & Schulze, U. Does size matter in R&D productivity? If not, what does? Nat. Rev. Drug Discov. 12, 901-902 (2013).
9. Arrowsmith, J. & Miller, P. Trial watch: phase II and phase III attrition rates 2011-2012. Nat. Rev. Drug Discov. 12, 569 (2013).
10. Hay, M., Thomas, D. W., Craighead, J. L., Economides, C. & Rosenthal, J. Clinical development success rates for investigational drugs. Nat. Biotechnol. 32, 40-51 (2014).
11. Peck, R. W., Lendrem, D. W., Grant, I., Lendrem, B. C. & Isaacs, J. D. Why is it hard to terminate failing projects in pharmaceutical R&D? Nat. Rev. Drug Discov. 14, 663-664 (2015).
12. Waring, M. J. et al. An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat. Rev. Drug Discov. 14, 475-486 (2015).
13. Smietana, K., Siatkowski, M. & Müller, M. Trends in clinical success rates. Nat. Rev. Drug Discov. 15, 379-380 (2016).
14. Harrison, R. K. Phase II and phase III failures: 2013-2015. Nat. Rev. Drug Discov. 15, 817-818 (2016).
15. Kassel, D. B. Applications of high-throughput ADME in drug discovery. Curr. Opin. Chem. Biol. 8, 339-345 (2004).
16. Wang, J. Comprehensive assessment of ADMET risks in drug discovery. Curr. Pharm. Des. 15, 2195-2219 (2009).
17. Wishart, D. S. Improving early drug discovery through ADME modelling: an overview. Drugs R D 8, 349-362 (2007).
18. De Buck, S. S. et al. Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs. Drug Metab. Dispos. 35, 1766-1780 (2007).
19. Jones, H. M., Gardner, I. B. & Watson, K. J. Modelling and PBPK simulation in drug discovery. AAPS J. 11, 155-166 (2009).
20. Bowes, J. et al. Reducing safety-related drug attrition: the use of in vitro pharmacological profiling. Nat. Rev. Drug Discov. 11, 909-922 (2012).
21. Segall, M. D. & Barber, C. Addressing toxicity risk when designing and selecting compounds in early drug discovery. Drug Discov. Today 19, 688-693 (2014).
22. Blomme, E. A. G. & Will, Y. Toxicology strategies for drug discovery: present and future. Chem. Res. Toxicol. 29, 473-504 (2016).
23. Prentis, R. A., Lis, Y. & Walker, S. R. Pharmaceutical innovation by the seven UK-owned pharmaceutical companies. Br. J. Clin. Pharmacol. 25, 387-396 (1988).
24. Bunnage, M. E. Getting pharmaceutical R&D back on target. Nat. Chem. Biol. 7, 335-339 (2011).
25. Deeks, S. G., Smith, M., Holodniy, M. & Kahn, J. O. HIV-1 protease inhibitors. A review for clinicians. JAMA 277, 145-153 (1997).
26. Olbe, L., Carlsson, E. & Lindberg, P. A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole. Nat. Rev. Drug Discov. 2, 132-139 (2003).
27. Simons, F. E. R. Advances in H1-antihistamines. N. Engl. J. Med. 351, 2203-2217 (2004).
28. Agarwal, P., Sanseau, P. & Cardon, L. R. Novelty in the target landscape of the pharmaceutical industry. Nat. Rev. Drug Discov. 12, 575-576 (2013).
29. Burnett, J. R. & Huff, M. W. Cholesterol absorption inhibitors as a therapeutic option for hypercholesterolaemia. Expert Opin. Investig. Drugs 15, 1337-1351 (2006).
30. Stoekenbroek, R. M., Kastelein, J. J. P. & Hovingh, G. K. Recent failures in antiatherosclerotic drug development. Curr. Opin. Lipidol. 24, 459-466 (2013).
31. Ikonomidou, C. & Turski, L. Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? Lancet Neurol. 1, 383-386 (2002).
32. Ho, L.-J. & Lai, J.-H. Small-molecule inhibitors for autoimmune arthritis: success, failure and the future. Eur. J. Pharmacol. 747, 200-205 (2015).
33. Nissen, S. E. et al. Effect of ACAT inhibition on the progression of coronary atherosclerosis. N. Engl. J. Med. 354, 1253-1263 (2006).
34. Meuwese, M. C. et al. ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial. JAMA 301, 1131-1139 (2009).
35. Damjanov, N., Kauffman, R. S. & Spencer-Green, G. T. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum. 60, 1232-1241 (2009).
36. Cohen, S. B. et al. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum. 60, 335-344 (2009).
37. Davis, S. M. et al. Selfotel in acute ischemic stroke: possible neurotoxic effects of an NMDA antagonist. Stroke 31, 347-354 (2000).
38. Albers, G. W., Goldstein, L. B., Hall, D. & Lesko, L. M. Aptiganel hydrochloride in acute ischemic stroke: a randomized controlled trial. JAMA 286, 2673-2682 (2001).
39. Sacco, R. L. et al. Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: a randomized controlled trial. JAMA 285, 1719-1728 (2001).
40. Heinonen, T. M. Inhibition of acyl coenzyme A-cholesterol acyltransferase: a possible treatment of atherosclerosis? Curr. Atheroscler. Rep. 4, 65-70 (2002).
41. Hoyte, L., Barber, P. A., Buchan, A. M. & Hill, M. D. The rise and fall of NMDA antagonists for ischemic stroke. Curr. Mol. Med. 4, 131-136 (2004).
42. McNamee, K., Williams, R. & Seed, M. Animal models of rheumatoid arthritis: how informative are they? Eur. J. Pharmacol. 759, 278-286 (2015).
43. Denayer, T., Stöhr, T. & Van Roy, M. Animal models in translational medicine: validation and prediction. New Horiz. Transl Med. 2, 5-11 (2014).
44. Karran, E., Mercken, M. & De Strooper, B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat. Rev. Drug Discov. 10, 698-712 (2011).
45. Soejitno, A., Tjan, A. & Purwata, T. E. Alzheimer's disease: lessons learned from amyloidocentric clinical trials. CNS Drugs 29, 487-502 (2015).
46. Le Couteur, D. G., Hunter, S. & Brayne, C. Solanezumab and the amyloid hypothesis for Alzheimer's disease. BMJ 355, i6771 (2016).
47. Selkoe, D. J. The therapeutics of Alzheimer's disease: where we stand and where we are heading. Ann. Neurol. 74, 328-336 (2013).
48. M. U.I. R., K. Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists. Curr. Opin. Pharmacol. 6, 53-60 (2006).
49. Langmead, C. J., Watson, J. & Reavill, C. Muscarinic acetylcholine receptors as CNS drug targets. Pharmacol. Ther. 117, 232-243 (2008).
50. Pal, P., Gandhi, H., Giridhar, R. & Yadav, M. R. ACAT inhibitors: the search for novel cholesterol lowering agents. Mini Rev. Med. Chem. 13, 1195-1219 (2013).
51. Karran, E. & Hardy, J. A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. Ann. Neurol. 76, 185-205 (2014).
52. Pangalos, M. N., Schechter, L. E. & Hurko, O. Drug development for CNS disorders: strategies for balancing risk and reducing attrition. Nat. Rev. Drug Discov. 6, 521-532 (2007).
53. McGonigle, P. Animal models of CNS disorders. Biochem. Pharmacol. 87, 140-149 (2014).
54. Pankevich, D. E., Altevogt, B. M., Dunlop, J., Gage, F. H. & Hyman, S. E. Improving and accelerating drug development for nervous system disorders. Neuron 84, 546-553 (2014).
55. Hait, W. N. Anticancer drug development: the grand challenges. Nat. Rev. Drug Discov. 9, 253-254 (2010).
56. Gould, S. E., Junttila, M. R. & de Sauvage, F. J. Translational value of mouse models in oncology drug development. Nat. Med. 21, 431-439 (2015).
57. Zitvogel, L., Pitt, J. M., Daillère, R., Smyth, M. J. & Kroemer, G. Mouse models in oncoimmunology. Nat. Rev. Cancer 16, 759-773 (2016).
58. Cessak, G. et al. TNF inhibitors-mechanisms of action, approved and off-label indications. Pharmacol. Rep. 66, 836-844 (2014).
59. Traxler, P. Tyrosine kinases as targets in cancer therapy-successes and failures. Expert Opin. Ther. Targets 7, 215-234 (2003).
60. Gschwind, A., Fischer, O. M. & Ullrich, A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat. Rev. Cancer 4, 361-370 (2004).
61. Gross, S., Rahal, R., Stransky, N., Lengauer, C. & Hoeflich, K. P. Targeting cancer with kinase inhibitors. J. Clin. Invest. 125, 1780-1789 (2015).
62. Pergola, C. & Werz, O. 5-Lipoxygenase inhibitors: a review of recent developments and patents. Expert Opin. Ther. Pat. 20, 355-375 (2010).
63. Di Gennaro, A. & Haeggström, J. Z. Targeting leukotriene B4 in inflammation. Expert Opin. Ther. Targets 18, 79-93 (2014).
64. Lee, K. et al. AMPA receptors as therapeutic targets for neurological disorders. Adv. Protein Chem. Struct. Biol. 103, 203-261 (2016).
65. King, H., Aleksic, T., Haluska, P. & Macaulay, V. M. Can we unlock the potential of IGF-1R inhibition in cancer therapy? Cancer Treat. Rev. 40, 1096-1105 (2014).
66. Goudreau, N. & Llinäs-Brunet, M. The therapeutic potential of NS3 protease inhibitors in HCV infection. Expert Opin. Investig. Drugs 14, 1129-1144 (2005).
67. Gentile, I., Coppola, N., Buonomo, A. R., Zappulo, E. & Borgia, G. Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus. Expert Opin. Investig. Drugs 23, 1211-1223 (2014).
68. Jadhav, M., Yeola, C., Zope, G. & Nabar, A. Aliskiren, the first direct renin inhibitor for treatment of hypertension: the path of its development. J. Postgrad. Med. 58, 32-37 (2012).
69. Jensen, C., Herold, P. & Brunner, H. R. Aliskiren: the first renin inhibitor for clinical treatment. Nat. Rev. Drug Discov. 7, 399-410 (2008).
70. Graham, W. V., Bonito-Oliva, A. & Sakmar, T. P. Update on Alzheimer's disease therapy and prevention strategies. Annu. Rev. Med. 68, 413-430 (2017).
71. Antonelli, G., Scagnolari, C., Moschella, F. & Proietti, E. Twenty-five years of type I interferon-based treatment: a critical analysis of its therapeutic use. Cytokine Growth Factor Rev. 26, 121-131 (2015).
72. Plenge, R. M., Scolnick, E. M. & Altshuler, D. Validating therapeutic targets through human genetics. Nat. Rev. Drug Discov. 12, 581-594 (2013).
73. Nelson, M. R. et al. The support of human genetic evidence for approved drug indications. Nat. Genet. 47, 856-860 (2015).
74. Renwick, M. J., Simpkin, V. & Mossialos, E. Targeting innovation in antibiotic drug discovery and development. The need for a One Health-One Europe-One World Framework (WHO, 2016).
75. Meekings, K. N., Williams, C. S. M. & Arrowsmith, J. E. Orphan drug development: an economically viable strategy for biopharma R&D. Drug Discov. Today 17, 660-664 (2012).
76. Graham, W. V., Bonito-Oliva, A. & Sakmar, T. P. Update on Alzheimer's disease therapy and prevention strategies. Annu. Rev. Med. 68, 413-430 (2017).
77. Antonelli, G., Scagnolari, C., Moschella, F. & Proietti, E. Twenty-five years of type I interferon-based treatment: a critical analysis of its therapeutic use. Cytokine Growth Factor Rev. 26, 121-131 (2015).
78. Plenge, R. M., Scolnick, E. M. & Altshuler, D. Validating therapeutic targets through human genetics. Nat. Rev. Drug Discov. 12, 581-594 (2013).
79. Nelson, M. R. et al. The support of human genetic evidence for approved drug indications. Nat. Genet. 47, 856-860 (2015).
80. Renwick, M. J., Simpkin, V. & Mossialos, E. Targeting innovation in antibiotic drug discovery and development. The need for a One Health-One Europe-One World Framework (WHO, 2016).
81. Meekings, K. N., Williams, C. S. M. & Arrowsmith, J. E. Orphan drug development: an economically viable strategy for biopharma R&D. Drug Discov. Today 17, 660-664 (2012).
82. Braun, M. M., Farag-El-Massah, S., Xu, K. & Cotë, T. R. Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years. Nat. Rev. Drug Discov. 9, 519-522 (2010).
83. Melnikova, I. Rare diseases and orphan drugs. Nat. Rev. Drug Discov. 11, 267-268 (2012).
84. Santos, R. et al. A comprehensive map of molecular drug targets. Nat. Rev. Drug Discov. 16, 19-34 (2017).